Beta Bionics, Inc. - Common Stock (BBNX)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — May 3, 2026Investment Snapshot
- P/B of 1.69 — trading above book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -30.1%
- Revenue growing at 54% annually
Beta Bionics, Inc. - Common Stock (BBNX) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NASDAQ , with a market capitalisation of $459 million . Key value metrics: P/B ratio 1.69, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 3 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Beta Bionics, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, BBNX shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -30.1% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.14.
StockPik's composite Value Score for BBNX is 52/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BBNX reports a solid gross margin of 55.4% (sector average: 40.1%) and a negative operating margin of -83.4%.
BBNX shows revenue growing at 54% year-over-year, with earnings declining at 34%.